A2 Refereed review article in a scientific journal

Quantitative approaches to 18F-flurpiridaz positron emission tomography image analysis



Authors: Packard, René R. Sevag; deKemp, Robert A.; Knuuti, Juhani; Moody, Jonathan B.; Renaud, Jennifer M.; Saraste, Antti; Slomka, Piotr J.

Publisher: Elsevier BV

Publishing place: NEW YORK

Publication year: 2025

Journal: Journal of Nuclear Cardiology

Journal name in source: Journal of Nuclear Cardiology

Journal acronym: J NUCL CARDIOL

Article number: 102180

Volume: 45

Number of pages: 16

ISSN: 1071-3581

eISSN: 1532-6551

DOI: https://doi.org/10.1016/j.nuclcard.2025.102180

Web address : https://doi.org/10.1016/j.nuclcard.2025.102180

Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/491896178


Abstract

Key points

18F-flurpiridaz is a positron emission tomography (PET) radiotracer for myocardial perfusion imaging (MPI) approved by the United States Food and Drug Administration in September 2024.

This radiotracer's properties, including a very high 94% myocardial first-pass extraction fraction and positron range of 1 mm, render this probe suitable for high-resolution MPI and quantitative myocardial blood flow (MBF) determination.

We present 18F-flurpiridaz in the context of other PET MPI radiopharmaceuticals, discuss pivotal experimental studies that provided the foundation for subsequent software-based quantitative strategies in humans, and detail the published methods of relative MPI as well as MBF quantitation.

The reviewed methods provide a standardization of 18F-flurpiridaz PET and MBF interpretation that are poised to facilitate this radiotracer's adoption and implementation in cardiac imaging centers.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Funding information in the publication: 
None.


Last updated on 2025-23-05 at 18:18